Impact of Guidelines on Outcome: The Evidence

Raquel Martínez; Soledad Reyes; Mª José Lorenzo; Rosario Menéndez

doi:10.1055/s-0029-1202936

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2009; 30(2): 172-178
DOI: 10.1055/s-0029-1202936

Impact of Guidelines on Outcome: The Evidence

Raquel Martínez¹ ^, ² ^, ³ , Soledad Reyes¹ , Mª. José Lorenzo¹ , Rosario Menéndez¹ ^, ²

¹Servicio de Neumología, Hospital Universitario La Fe, Valencia, Valencia, Spain
²Ciber de Enfermedades Respiratorias (CIBERES), Valencia, Spain
³Department of Medicine-Doctoral Programme, Autonomous University of Barcelona, Barcelona, Spain

Abstract

ABSTRACT

Pneumonia continues to be the main cause of death due to infection in the world, and it produces a high consumption of healthcare resources. The guidelines established by the scientific societies improve the care of patients with pneumonia. One way of evaluating the effect of the guidelines is to analyze their impact on the prognosis of the infection. To evaluate this effect, cohort studies have been performed using before–after, observational, cost-effectiveness, and, to a lesser degree, randomized designs. The most recent studies show that the implementation of the guidelines is accompanied by an increase in the process of care percentage and a lower inpatient hospital mortality rate— including the first 48 hours and after 30 days. These findings are consistent across various studies, and they have been confirmed in patients admitted to the intensive care unit. Clinical stability is also reached earlier in patients hospitalized for community-aquired pneumonia (CAP) when the antibiotic treatment is begun early and complies with the recommendations. Finally, the choice of antibiotics that adhere to the guidelines is cost-effective in CAP requiring hospitalization, which is responsible for 80% of the total cost of this disease.

KEYWORDS

Mortality - stability - cost-effectiveness - treatment failure - pathway

Full Text

References

REFERENCES

1 Minino A M, Smith B L. Deaths: preliminary data for 2000. Natl Vital Stat Rep. 2001; 49 1-40
2 European Respiratory Society . Pneumonia. In: Loddenkemper R European Lung White Book. Loussane; 2003: 55-65
3 Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998; 20 820-837
4 Monge V, San-Martin V M, Gonzalez A. The burden of community-acquired pneumonia in Spain. Eur J Public Health. 2001; 11 362-364
5 Alfageme I, Aspa J, Bello S et al.. Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2005; 41 272-289
6 Mandell L A, Wunderink R G, Anzueto A et al.. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia. Clin Infect Dis. 2007; 44 S27-S72
7 Woodhead M. Community-acquired pneumonia guidelines: an international comparison: a view from Europe. Chest. 1998; 113(3 Suppl) 183S-187S
8 Barlow G D, Lamping D L, Davey P G, Nathwani D. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Lancet Infect Dis. 2003; 3 476-488
9 Houck P M, Bratzler D W, Nsa W, Ma A, Bartlett J G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004; 164 637-644
10 Waterer G W, Kessler L A, Wunderink R G. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest. 2006; 130 11-15
10a Rhew D C. Quality indicators for the management of pneumonia in vulnerable elders. Ann Intern Med. 2001; 135 736-743
11 Barlow G, Nathwani D, Williams F et al.. Reducing door-to-antibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and cost-effectiveness analysis. Thorax. 2007; 62 67-74
12 Cabana M D, Rand C S, Powe N R et al.. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999; 282 1458-1465
13 Halm E A, Atlas S J, Borowsky L H et al.. Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. Arch Intern Med. 2000; 160 98-104
14 Schouten J A, Hulscher M E, Kullberg B J et al.. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors. J Antimicrob Chemother. 2005; 56 575-582
15 Rello J, Lorente C, Bodi M, Diaz E, Ricart M, Kollef M H. Why do physicians not follow evidence-based guidelines for preventing ventilator-associated pneumonia? A survey based on the opinions of an international panel of intensivists. Chest. 2002; 122 656-661
16 Davey P G, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect. 2008; 14(Suppl 3) 15-21
17 Bjerre L M, Verheij T J, Kochen M M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2004; (2) CD002109
18 Gleason P P, Kapoor W N, Stone R A et al.. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA. 1997; 278 32-39
19 Suchyta M R, Dean N C, Narus S, Hadlock C J. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med. 2001; 110 306-309
20 Dean N C, Silver M P, Bateman K A, James B, Hadlock C J, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 2001; 110 451-457
21 Menéndez R, Torres A, Zalacain R et al.. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med. 2005; 172 757-762
22 Dean N C, Bateman K A, Donnelly S M, Silver M P, Snow G L, Hale D. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest. 2006; 130 794-799
23 Capelastegui A, Espana P P, Quintana J M et al.. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis. 2004; 39 955-963
24 Menéndez R, Ferrando D, Valles J M, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest. 2002; 122 612-617
25 Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D. Can CAP guideline adherence improve patient outcome in internal medicine departments?. Eur Respir J. 2008; 32 902-910
26 Mortensen E M, Restrepo M I, Anzueto A, Pugh J A. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med. 2006; 119 859-864
27 Bodi M, Rodriguez A, Sole-Violan J et al.. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005; 41 1709-1716
28 Shorr A F, Bodi M, Rodriguez A, Sole-Violan J, Garnacho-Montero J, Rello J. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest. 2006; 130 93-100
29 Reyes S, Martinez R, Valles J M, Cases E, Menéndez R. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J. 2008; 31 1061-1067
30 Menéndez R, Ferrando D, Valles J M, Martinez E, Perpina M. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur Respir J. 2001; 18 151-156
31 Dudas V, Hopefl A, Jacobs R, Guglielmo B J. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000; 34 446-452
32 Stahl J E, Barza M, DesJardin J, Martin R, Eckman M H. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med. 1999; 159 2576-2580
33 Gleason P P, Meehan T P, Fine J M, Galusha D H, Fine M J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999; 159 2562-2572
34 Arnold F W, Summersgill J T, Lajoie A S et al.. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007; 175 1086-1093
35 Menéndez R, Torres A, Rodriguez de Castro F et al.. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis. 2004; 39 1783-1790
36 Marrie T J, Lau C Y, Wheeler S L, Wong C J, Vandervoort M K, Feagan B G. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000; 283 749-755
37 Meehan T P, Weingarten S R, Holmboe E S et al.. A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project. Am J Med. 2001; 111 203-210
38 Frei C R, Restrepo M I, Mortensen E M, Burgess D S. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med. 2006; 119 865-871
39 Battleman D S, Callahan M, Thaler H T. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002; 162 682-688
40 Orrick J J, Segal R, Johns T E, Russell W, Wang F, Yin D D. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics. 2004; 22 751-757
41 Menéndez R, Reyes S, Martinez R, de la Cuadra P, Manuel Valles J, Vallterra J. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia. Eur Respir J. 2007; 29 751-756
42 Gora-Harper M L, Rapp R P, Finney J P. Development of a best-practice model at a university hospital to increase efficiency in the management of patients with community-acquired pneumonia. Am J Health Syst Pharm. 2000; 57(Suppl 3) S6-S9

Rosario MenéndezM.D. Ph.D.

Servicio de Neumología, Hospital Universitario La Fe, Valencia

Avda de Campanar 21, 46009 Valencia, Spain

Email: rmenend@separ.es